Physician profile
Reena Loona
NPI 1073676060
$2,365.21
in general payments reported to CMS, 2019-2025
26 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $115 · 2021: $290 · 2022: $222 · 2023: $271 · 2024: $112 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $812.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $360.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Biotech, INC. | $209.82 | 2019-2021 | |
| Lilly USA, LLC | $189.00 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $163.94 | 2019-2025 | |
| Globus Medical, INC. | $153.98 | 2025 | Senza |
| Horizon Therapeutics Plc | $148.85 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $137.81 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $122.17 | 2019 | |
| Amgen INC. | $112.23 | 2019-2024 | Otezla, Repatha |
| Depuy Synthes Sales INC. | $99.72 | 2019 | |
| Astellas Pharma US INC | $94.43 | 2023-2024 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $83.40 | 2022-2025 | Airsupra, Breztri |
| Pfizer INC. | $82.95 | 2019-2025 | |
| Gilead Sciences, INC. | $72.45 | 2019 | |
| Intra-Sana Laboratories | $53.71 | 2023 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $42.83 | 2021-2023 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.63 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.64 | 2019 | |
| Tandem Diabetes Care, INC. | $29.00 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $24.81 | 2022 | |
| Glaxosmithkline, LLC. | $24.25 | 2022 | |
| Electromed, INC. | $22.89 | 2023 | Smartvest |
| Idorsia Pharmaceuticals US INC | $21.84 | 2023 | Quviviq |
| Medtronic, INC. | $20.07 | 2025 | Minimed 780g |
| Endo Pharmaceuticals INC. | $15.79 | 2019 | |
| Amarin Pharma, INC. | $15.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Loona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.